# IMCODE001 (NCT03815058)

> A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran (RO7198457) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Participants With Previously Untreated Advanced Melanoma.

No report yet. It can be ordered.

- Drugs tested: autogene cevumeran plus pembrolizumab
- Indication: previously untreated advanced melanoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03815058
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Genentech, Inc.
- Conditions: Advanced Melanoma
- Interventions: Autogene cevumeran; Pembrolizumab
- Enrollment: 131
- Primary outcome: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v.1.1) After Randomization

## Indexed commentary on IMCODE001 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3
- YouTube: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=imcode001-nct03815058